New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Ajovy fremanezumab |
Teva | An injectable anti-calcitonin gene-related peptide for migraine prevention in adults. |
|
Anthim obiltoxaximab |
Elusys (U.S.) | An injectable monoclonal antibody for treatment and postexposure prophylaxis of inhalational anthrax. |
|
Avsola infliximab |
Amgen | Biosimilar to Remicade. |
|
Beovu brolucizumab |
Novartis | Intravitreal VEGF inhibitor for neovascular (wet) age-related macular degeneration. |
|
Cabenuva cabotegravir/rilpivirine |
ViiV Healthcare | Extended-release injectable formulation for HIV-1 infection. |
|
Cablivi caplacizumab |
Sanofi Genzyme | An injectable antithrombotic for acquired thrombotic thrombocytopenic purpura. |
|
Darzalex SC daratumumab |
Janssen | New subcutaneous formulation for multiple myeloma. |
|
Daurismo glasdegib |
Pfizer | An oral Hedgehog pathway inhibitor for newly-diagnosed acute myeloid leukemia. |
|
Enspryng satralizumab |
Hoffmann-La Roche | An injectable monoclonal antibody for neuromyelitis optica spectrum disorders. |
|
Firdapse amifampridine |
Catalyst Pharma (U.S.)/Kye Pharm | An oral potassium channel blocker for Lambert-Eaton myasthenic syndrome. |
|
Gleolan aminolevulinic acid |
Medexus | An oral imaging agent used in patients with glioma to help visualize malignant tissue during surgery. |
|
Ibsrela tenapanor |
Knight Therapeutics | An oral sodium/hydrogen exchanger 3 (NHE3) inhibitor for IBS-C. |
|
Inqovi decitabine/cedazuridine |
Otsuka | An oral hypomethylating agent for myelodysplastic syndromes. |
|
Inrebic fedratinib |
Celgene | New oral kinase inhibitor for splenomegaly and/or disease-related symptoms in patients with myelofibrosis. |
|
Itulatek white birch allergen extract |
Alk-Abello | SL allergy immunotherapy for moderate to severe seasonal allergic rhinitis induced by pollen from birch, alder, and/or hazel. |
|
Kanjinti trastuzumab |
Amgen | Biosimilar to Herceptin. |
|
Mayzent siponimod |
Novartis | An oral sphingosine 1-phosphate receptor modulator for multiple sclerosis. |
|
Nivestym filgrastim |
Pfizer | A biosimilar to Neupogen. |
|
Nubeqa darolutamide |
Bayer | An oral antiandrogen for non-metastatic castration resistant prostate cancer. |
|
Odomzo sonidegib |
Sun Pharma | Oral hedgehog pathway inhibitor for basal cell carcinoma. |
|
Osnuvo teriparatide |
Avir Pharma | A biosimilar to Forteo. |
|
Piqray alpelisib |
Novartis | Oral kinase inhibitor for advanced/metastatic breast cancer. |
|
Polivy polatuzumab |
Hoffmann-La Roche | A monoclonal antibody for relapsed/refractory diffuse large B-cell lymphoma. |
|
Qinlock ripretinib |
Deciphera (US) | Oral kinase inhibitor for gastrointestinal stromal tumours. |
|
Reblozyl luspatercept |
Celgene/BMS | A erythroid maturation agent for red blood cell transfusion-dependent anemia in adults with beta-thalassemia. |
|
Riximyo rituximab |
Sandoz | A biosimilar to Rituxan. |
|
Rozlytrek entrectinib |
Hoffmann-La Roche | A tyrosine kinase inhibitor for advanced extracranial solid tumours, including brain metastases. |
|
Ruxience rituximab |
Pfizer | A biosimilar to Rituxan. |
|
Ruzurgi amifampridine |
Medunik Canada | An oral potassium channel blocker for Lambert-Eaton myasthenic syndrome. |
|
Sarclisa isatuximab |
Sanofi-Aventis | A monoclonal antibody for refractory multiple myeloma. |
|
Spravato esketamine |
Janssen | An intranasal NMDA antagonist for depression. |
|
Tomvi etomidate |
Sterimax | A new injectable general anesthetic. |
|
Tukysa tucatinib |
Seattle Genetics | An oral kinase inhibitor for advanced HER2-positive breast cancer. |
|
Veklury remdesivir |
Gilead Canada | An injectable nucleotide prodrug for adult/adolescent COVID-19 patients with pneumonia requiring supplemental oxygen. |
|
Vocabria cabotegravir |
ViiV Healthcare | Oral formulation (used with oral rilpivirine) for short-term treatment of HIV-1 infection (used before starting Cabenuva to assess tolerability or as oral bridging therapy for missed Cabenuva injections). |
|
Vyndaqel tafamidis meglumine |
Pfizer | An oral transthyretin stabilizer for cardiomyopathy due to transthyretin-mediated amyloidosis. |
|
Xenleta lefamulin |
Sunovion | An injectable pleuromutilin antibiotic for community-acquired pneumonia. |
|
Xofluza baloxavir marboxil |
Hoffmann-La Roche | An oral antiviral for treating influenza. |
|
Zeposia ozanimod |
Celgene/BMS | An oral sphingosine 1-phosphate receptor modulator for relapsing remitting MS. |
|
Ziextenzo pegfilgrastim |
Sandoz | A biosimilar to Neulasta. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Atectura Breezhaler indacaterol/mometasone |
Novartis | A combination inhaled LABA/corticosteroid for maintenance treatment of asthma. |
|
Bijuva estradiol/progesterone |
Knight Therapeutics | New capsule formulation for vasomotor symptoms associated with menopause. |
|
Duobrii halobetasol/tazarotene |
Bausch Health | New formulation corticosteroid/retinoid lotion for plaque psoriasis. |
|
Enerzair Breezhaler indacaterol/glycopyrronium/mometasone |
Novartis | New combination long-acting bronchodilator/steroid inhaler for asthma maintenance therapy. |
|
Imvexxy estradiol |
Knight Therapeutics | Vaginal estrogen formulation for moderate to severe postmenopausal dyspareunia. |
|
Kynmobi apomorphine |
Sunovion | Sublingual dopamine agonist for acute intermittent off episodes in Parkinson’s disease. |
|
Nexplanon etonogestrel |
Merck | New subdermal implant formulation for contraception. |
|
Peyona caffeine citrate |
Chiesi (Spain) | CNS stimulant for primary apnea in premature newborns. |
|
Suboxone buprenorphine/ naloxone |
Indivior | New sublingual/buccal soluble film for opioid drug dependence. |
|
Suvexx sumatriptan/naproxen |
Nuvo Pharm. | New oral triptan/NSAID combination for acute migraine. |
|
Uceris budesonide |
Bausch Health | New rectal foam formulation for mild to moderate ulcerative colitis. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Fibristal ulipristal |
Allergan/AbbVie | Voluntary withdrawal from market by manufacturer due to risk of serious liver injury. |